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Can the optimum artificial tear treatment for dry eye disease be predicted from presenting signs 
and symptoms? 
Abstract 
Purpose To assess dry eye treatment with four preservative-free dry eye artificial tear 
treatments to facilitate evidence-based prescribing.  
Methods A randomised, single masked crossover trial of Clinitas Soothe, Hyabak, Tears Again 
and TheraTears artificial tears was conducted on 50 symptomatic dry eye patients, aged 60.8±14.2 
years. At baseline and after trialling each treatment for 4 weeks, signs and symptoms were assessed 
using the Ocular Surface Disease Index (OSDI), non-invasive tear break-up time, fluorescein tear 
break-up time, tear meniscus height (TMH), Phenol Red test, lid-parallel conjunctival folds (LIPCOF), 
ocular surface staining, and lipid layer grading and osmolarity (baseline visit only).       
Results  The impact of each dry eye treatment on ocular signs and symptoms was similar, 
however OSDI (p=0.002), LIPCOF (p=0.014) and conjunctival staining (p<0.001) significantly improved 
from baseline. Clinitas Soothe and Hyabak were preferred by 34%/30% of participants, but only 
subjective comparison with the other drops influenced this choice. TheraTears was preferred (by 
24%) by those with a lower baseline tear volume (p=0.01) and Tears Again (by 12%) by those with a 
thinner baseline lipid layer (p=0.04). The treatment that afforded the greatest improvement in 
clinical signs did not consistently match each individual’s preferred treatment. 
Conclusions If prescribed to a general dry eye population, the artificial tears performed similarly, 
improving symptoms and conjunctival signs. However, osmolarity balanced artificial tears were the 
preferred treatment in individuals with low baseline tear volume and lipisomal spray for individuals 
with a baseline lipid layer deficiency.  
Key words 
Dry eye; carboxymethylcellulose; liposomal spray; sodium hyaluronate; randomised control trial; 
artificial tears  
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Highlights 
• In a general dry eye population, the artificial tears tested performed similarly 
• Treatment effects still evident  after 4 months of treatment 
• Artificial tears provide more than transient relief to symptoms 
• Artificial tears aid in breaking the vicious dry eye disease cycle 
• Osmolarity balanced drops preferred by those with low baseline tear volume 
• Lipisomal spray preferred treatment by those with baseline lipid layer deficiency 
 
Introduction 
Dry eye signs and symptoms are typically triggered by a dysfunction of the ocular tear film, which 
may arise due to deficiencies in the aqueous phase of the tear film (termed aqueous-deficient dry 
eye) and, more commonly, the lipid phase of the tear film (termed evaporative dry eye) [1]. The 
primary course of dry eye treatment is topical application of eye drops, gels and sprays to re-build 
and stabilise the tear film. Numerous compositions of dry eye treatments are commercially 
available, principally differing in which element of the tear film they primarily aim to replace. Sodium 
hyaluronate is a glycosaminoglycan with viscoelastic properties2 that increases tear film stability [2-
4] and increases epithelial cell migration [5-6]. Carboxymethylcellulose (CMC) is an anionic cellulose 
polymer with a carboxylic group, which exhibits a high affinity for bioadhesion [7], increases tear film 
stability3 and increases epithelial cell migration [8]. Liposomal dry eye treatments consist of 
phospholipids, which enhance the lipid tear film layer [9] and also increase tear film stability [9-11]. 
Osmolarity is considered a key driver of ocular surface damage from dry eye [12] and an artificial 
tear has been formulated to overcome this but this has not been extensively tested clinically against 
other treatment options [13]. Approximately 78% of dry eye patients have been reported to have 
lipid layer deficiencies [1], therefore Lee and colleagues recommended liposomal sprays should be 
the first choice of treatment for all dry eye patients [14]. However previous studies tend to compare 
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the benefit of one ‘class’ of artificial tear, with perhaps saline as a control, some over short 
durations, rather than cross class to inform optimum prescribing decisions (Table 1). 
 
Despite knowing that artificial treatment individually help to reduce symptoms compared to a saline 
placebo, evidence-based criteria indicating which composition of treatment is best suited to alleviate 
particular dry eye signs and symptoms are currently unavailable. The aim of the current study was to 
compare the performance of four commercially available preservative-free dry eye treatments 
compared to baseline dry eye assessment in a randomised controlled crossover trial, in order to 
facilitate evidence-based dry eye treatment prescribing.  
 
Study Drops Used Tests 
compared 
Design Sample Size Evaluation 
period 
Conclusions 
Brignole et 
al. 2005 
[15]  
• Sodium hyaluronate 
(0.18%) 
• CMC (1%) 
• Flow 
cytometry  
• Subjective 
reports 
Randomised, 
double-
masked, non-
crossover 
study 
22 (100% 
documented 
history of 
moderate dry eye) 
2 months 
(instilled 3 
times daily) 
• Sodium hyaluronate 
improvement of 
comfort & reduction in 
CD44 expression 
superior when 
compared with CMC  
• CMC caused blurred 
vision 
Dausch et 
al. 2006 
[10]  
• Tears Again liposomal 
spray 
• Eye gel containing 
triglycerides 
• LIPCOF 
• TBUT 
• Schirmer’s 
• Eyelid health 
• Visual acuity 
• Subjective 
reports 
Randomised 
controlled, 
multi-centre, 
crossover 
study 
74 (100% lipid layer 
disturbances14)  
6 weeks 
(instilled 3 
times daily) 
• LIPCOF, TBUT, 
Schirmer’s, eyelid 
health, visual acuity & 
comfort were superior 
after liposomal spray 
treatment 
Johnson et 
al. 2006 [2]  
• Sodium hyaluronate 
(0.1%) 
• Sodium hyaluronate 
(0.3%) 
• Saline (control) 
• NITBUT 
• Subjective 
reports 
Randomised 
controlled 
crossover 
study 
13 (100% moderate 
dry eye) 
6 hours • NITBUT & comfort 
improvement was 
greater with sodium 
hyaluronate 0.3% than 
0.1% 
Craig et al. 
2010 [9]  
• Tears Again Liposomal 
spray  
• Saline (control) 
• LLG 
• NITBUT 
• TMH 
• Subjective 
reports 
Randomised, 
double-
masked, 
contralateral 
eye study   
22 (18% had 
borderline dry eye 
according to 
McMonnies Dry 
Eye 
Questionnaire13) 
135 minutes 
(single 
application) 
• LLG, NITBUT & comfort 
improvement was 
superior after liposomal 
spray treatment  
• TMH did not change 
Lee et al. 
2011 [3]  
• Sodium hyaluronate 
(0.1%) 
• CMC (0.5%) 
• NaFl staining 
• TBUT 
• Subjective 
reports 
Randomised, 
double-
masked, non-
crossover 
study 
65 (100% mild to 
moderate dry eye 
according to 
unspecified 
criteria) 
8 weeks  
(6 times daily) 
• NaFl staining, TBUT & 
symptoms improvement 
was not significantly 
different between 
treatment types 
Evangelista 
et al. 2011 
[17] 
• Carnidrop 
• Optive 
• Blu Sal 
• TBUT 
• Ocular 
protection 
index 
Randomised, 
double-
masked, non-
crossover 
study 
27 (moderate – 
DEWS 
classification) 
15 and 60 
minutes 
• Carnidrop outperformed 
comparators 
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Pult et al. 
2012 [11]  
• Optrex ActiMist 
• Dry Eyes Mist 
• Tear Mist 
• OSDI 
• NITBUT 
Randomised, 
multi-centred, 
double-
masked, 
contralateral 
eye study 
80 (26.9% had dry 
eye according to 
OSDI) 
10 minutes 
(single 
application) 
• Optrex ActiMist  
significantly  improved  
OSDI & NITBUT 
• Tear Mist  &  Dry Eyes 
Mist  reduced OSDI & 
NITBUT 
Baeyens et 
al. 2012 
[18] 
• Hyaluronate sodium 
(0.18%) 
• Carbomer (0.3%) 
• Saline 
• Symptoms 
• Fluorescein 
staining 
Randomised, 
double-
masked, non-
crossover 
study 
304 84 days 
(instilled 2-4 
times daily) 
• Sodium hyluronate 
outperformed other 
treatments 
Barabino 
et al. 2014 
[19] 
• Hyaluronic acid and 
tamarind seed 
polysaccharide 
• Carmellose sodium 
• OSDI 
• TBUT 
• Schirmer 
• Corneal & 
conjunctival 
staining 
Randomised, 
double-
masked, non-
crossover 
study 
49 (moderate dry 
eye) 
3 months 
(instilled 4 
times daily) 
• Formulations equally 
effective in reducing 
symptoms and staining. 
No effect on tear 
volume. 
Simmons 
et al. 2015 
[20] 
• Lipid-based tear 
formulations containing 
carboxymethylcellulose, 
glycerin, polysorbate 
80, and emulsified lipid 
• Subjective 
Evaluation of 
Symptom of 
Dryness 
• OSDI 
Randomised, 
double-
masked, non-
crossover 
study 
256 (reduced TBUT 
and staining) 
3 months 
(instilled 1-2 
times daily) 
• Formulations non-
inferior to existing lipid 
based product 
Simmons 
et al. 2015 
[21] 
• Carmellose sodium 
• Hyaluronic acid at 
different 
concentrations and 
osmoprotectants 
• Standard carmellose 
sodium-containing 
formulation (Refresh 
Tears) 
• OSDI Randomised, 
double-
masked, non-
crossover 
study 
305 (mild-to-
moderate signs of 
dry eye, an OSDI 
score of 18–65, 
TBUT <10s & 
currently using 
artificial tears 
3 months 
(instilled ≥2 
times daily) 
• Reduction in symptoms 
with all formulations, 
but differences between 
them in patients with 
pre-existing staining. 
Perez-
Balbuena 
et al. 2016 
[22] 
• Xanthan gum 
• Chondroitin sulfate 
preservative free 
• Schirmer 
• TBUT 
• OSDI 
Randomised, 
double-
masked, non-
crossover 
study 
148 2, 7, 15, 30 
and 60 days 
• Xanthan 
gum/chondroitin sulfate 
preservative free 
showed similar clinical 
efficacy 
Table 1: Summary of dry eye studies comparing artificial tears dry eye treatments on patients 
without Sjögren’s syndrome. OSDI= Ocular Surface Disease Index; NITBUT= Non-
Invasive Tear Break-Up Time; TBUT=fluorescein Tear Break-Up Time; LLG= Lipid 
Layer Grade; TMH= Tear Meniscus Height; LIPCOF= Lid Parallel Conjunctival Folds; 
CD44= hyaluronate receptor  
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Method 
The study was approved by the Aston University Ethics Committee and was conducted in accordance 
with the tenets of the Declaration of Helsinki. It was registered as a clinical trial with 
www.clinicaltrials.gov (Identifier: NCT02420834). Symptomatic dry eye patients (Ocular Surface 
Disease Index (OSDI) questionnaire score ≥13) [23], were recruited from a community optometric 
practice in North West England and were screened to exclude those with history of previous ocular 
or intraocular surgery, evidence of acute or chronic infections or an inflammatory condition of the 
cornea and conjunctiva, a positive history of systemic disease, hay fever, contact lens wear, punctal 
plug occlusion, use of topical ocular medications, pregnancy or a history of intolerance or 
hypersensitivity to any component of the study medications. No other tear film stability, volume or 
ocular surface damage requirements were applied to avoid selection bias in the general prescribing 
guidance objective of the study [12]. Informed written consent was obtained from all the 
participants after an explanation of the nature and possible consequences of the study. 
The study design was a single-masked randomised crossover trial, involving four commercially 
available dry eye treatments selected to represent viscosity increasing, lipid replacement and 
osmolarity balancing approach ‘classes’. Fifty symptomatic dry eye patients (70% female) with a 
mean age of 60.8 ± 14.2 years (range 26 to 82 years) participated in the study. Prior to the initiation 
of treatment, baseline dry eye symptoms were quantified using the OSDI questionnaire [23], 
generating a severity score between 0 and 100. Dry eye diagnosis for inclusion was defined as an 
OSDI ≥50. Baseline anterior eye examination included non-invasive break-up time (NITBUT) using a 
Tearscope Plus (Keeler Ltd, Windsor, UK) averaging 3 readings, lipid layer thickness analysis using a 
Tearscope Plus, osmolarity (highest value from the two eyes) using a TearLab (TearLab Ltd, 
California, USA), tear meniscus height (TMH) measurement (25x magnification from a slit-lamp 
biomicroscope with graticule), lid parallel conjunctival folds (LIPCOF) counted and graded under 25x 
magnification [24], the Phenol Red Test (PRT), fluorescein tear break-up time (NaFl TBUT), corneal 
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fluorescein staining assessment (graded against an Efron grading scale) and conjunctival staining 
assessment using Lissamine green (graded against an Oxford grading scale).       
Participants were prescribed preservative-free Clinitas Soothe (Farmigea SpA., Pisa Italy), Hyabak 
(Laboratories Théa, Clermont-Ferrand, France), Tears Again (Optima Pharmazeutische GmbH., 
Freising, Germany) and TheraTears (Advanced Vision Research Inc., Massachusetts, USA) in a 
randomised order each treatment to be used for four weeks as this is typical of artificial tear studies 
(Table 2) [25]. Each participant was also asked to keep a diary to document how many times a day 
the treatment was applied as often as required. The baseline tests described previously were 
repeated at the end of each treatment phase (except for osmolarity and lipid grade) and overall 
comfort, ease of insertion and visual clarity were graded on a visual analogue scale (out of 10), prior 
to a 4 day ‘wash-out’ period between treatments (no use of artificial tears or other dry eye 
management therapy). An appropriate wash-out period with artificial tears has not been 
established, but the randomised repeated measures design overcomes any bias of any 
improvements in the ocular surface beyond the wash-out period. A forced choice preference for one 
of the 4 artificial treatments was elicited at the end of the study.   
 
Brand name Ingredients Form 
Clinitas 
Soothe 
Sodium hyaluronate (0.4%), monobasic sodium phosphate, 
dibasic sodium phosphate, sodium chloride, water 
20 re-sealable droppers, 
of 8-10 drops each 
Hyabak Sodium hyaluronate (0.15%), sodium chloride, trometamol, 
hydrochloric acid, water 
10 ml bottle  
TheraTears Sodium carboxymethylcellulose (0.25%), borate buffers, 
calcium chloride, Dequest®, magnesium chloride, potassium 
chloride, purified water, sodium bicarbonate, sodium 
chloride, sodium perborate, sodium phosphate 
32 single use containers  
Tears Again Phospholipid liposomes, soy lecithin, sodium chloride, 
ethanol, phenoxyethanol, vitamin A, vitamin E, aqua 
purificata 
10ml bottle  
Table 2: The ingredients of Clinitas Soothe, Hyabak, TheraTears and Tears Again and the form 
supplied to each participant. The bold ingredient depicts the key lubricant.  
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Statistical analysis 
Assessment of normal distribution using one-Sample Kolmogorov-Smirnov Tests showed that only 
NITBUT of the metrics used in this study was normally distributed. Where data was normally 
distributed, repeated measure analysis of variance was conducted whereas all other measurements 
were assessed with related-samples Friedman’s two-way analysis of variance by ranks. The data 
were analysed using SPSS 20 software (IBM Corporation, New York, USA). Due to the repeated 
measures design of the study (four artificial tears each tested on 50 subjects) more than the 15 
degrees of freedom were achieved in the replicates to allow sufficient statistical power to detect 
differences in all the metric assessed [26]. 
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Results 
Usage 
The artificial tears were used on average similarly across all the types (Clinitas Soothe 2.1 ± 
1.2times/day; Hyabak 2.6 ± 1.8 times/day; Tears Again 2.3 ± 1.2 times/day; Theratears 2.5 ± 1.6 
times/day; p = 0.121) according to the diaries of daily use. 
Effectiveness of Treatments 
Signs, symptoms and patient satisfaction were similar after treatment with each of the four artificial 
tear supplements (Table 3), but were significantly better than pre-treatment for OSDI symptoms 
(Figure 1) and signs of LiPCOF (Figure 2) and conjunctival staining (Figure 3). 
 Artificial Tears (after 4 weeks) Baseline 
 Clinitas 
Soothe 
Hyabak Tears 
Again 
Theratears Significance 
between 
treatments  
Value Significance 
vs treatments 
OSDI 28.8 ± 21.2 23.6 ± 18.8 27.7 ± 20.9 28.9 ± 18.4 p=0.521 33.9 ± 20.0 p=0.002 
NITBUT (s) 13.3 ± 2.6 13.6 ± 2.4 13.2 ± 2.2 13.3 ± 2.4 F=1.315, p=0.272 13.2 ± 1.9 F=0.959, p=0.431 
NaFl TBUT (s) 13.5 ± 2.7 13.7 ± 2.7 13.7 ± 2.4 13.8 ± 2.4 p=0.225 13.2 ± 2.4 p=0.588 
TMH (mm) 0.11 ± 0.01 0.11 ± 0.02 0.11 ± 0.01 0.11 ± 0.01 p=0.443 0.11 ± 0.02 p=0.184 
Phenol Red 
Test (mm) 
14.1 ± 4.6 14.0 ± 4.4 14.0 ± 4.2 14.0 ± 4.5 p=0.724 14.1 ± 5.1 p=0.797 
LIPCOF 1.4 ± 0.8 1.2 ± 0.9 1.3 ± 0.7 1.4 ± 0.7 p=0.688 1.6 ± 0.8 p=0.014 
Corneal 
staining 
0.04 ± 0.30 0.08 ± 0.40 0.00 ± 0.00 0.12 ± 0.44 p=0.137 0.08 ± 0.27 p=0.218 
Conjunctival 
staining 
0.88 ± 1.00 0.92 ± 0.99 0.88 ± 0.98 1.02 ± 1.00 p=0.752 1.64 ± 0.75 p<0.001 
Overall 
comfort 
5.6 ± 2.6 6.2 ± 2.6 5.9 ± 2.7 5.9 ± 2.8 P=0.658   
Ease of 
insertion 
6.0 ± 2.5 6.9 ± 2.0 7.1 ± 2.1 6.5 ± 2.4  P=0.081   
Visual clarity 6.2 ± 2.5 6.9 ± 2.0 7.1 ± 1.8 6.5 ± 2.5 P=0.534   
Table 3: Average ± SD of dry eye signs, symptoms and patient ratings at baseline and after 4 
weeks treatment with each of Clinitas Soothe, Hyabak, TheraTears and Tears Again. 
N=50. OSDI= Ocular Surface Disease Index; NITBUT= Non-Invasive Tear Break-Up 
Time; NaFl TBUT = fluorescein Tear Break-Up Time, TMH= Tear Meniscus Height; 
LIPCOF= Lid Parallel Conjunctival Folds. Bold p values denote statistical significance. 
N=50.  
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Figure 1: Ocular comfort as measured by the OSDI questionnaire box plot (the boundaries of 
the box indicates the 25th and 75th percentile, the solid line within the box marks the 
median and the dashed line the mean, the error bars indicate the 90th and 10th 
percentiles and the dots the outliers) with the four different artificial tears used. 
n=50. 
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Figure 2:  LIPCOF box plot (the boundaries of the box indicates the 25th and 75th percentile, the 
dashed line the mean, the error bars indicate the 90th and 10th percentiles and the 
dots the outliers) with the four different artificial tears used. Medians were all 2 
except for 1 for Hyabak. n=50. 
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Figure 3:  Conjunctival Staining (the boundaries of the box indicates the 25th and 75th 
percentile which coincide with the 90th and 10th percentiles and there were no 
outliers; the dashed line indicates the mean) with the four different artificial tears 
used. Medians were all 2 as were the baseline 25th and 75th percentiles. n=50. 
 
 
Treatment effect with time 
NITBUT, Nafl TBUT, Phenol Red test, TMH and corneal staining showed no treatment effect with 
time (p>0.05; Table 4). OSDI results showed a significant treatment effect with time between the 
first and last 2 months (p>0.05), whereas lid parallel conjunctival folds (p=0.014) and conjunctival 
staining (p=0.002) showed a significant treatment effect from the first to the fourth month of 
treatment only. Patient ratings of overall comfort (between first and last 2 months; p<0.05), and 
clarity of vision (between second and fourth month; p=0.036) after instilling the drops significantly 
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improved with time, whereas ease of insertion was similar over the 4 month treatment period (Table 
4). 
 Visit Month 
 1 2 3 4 Significance  
OSDI 29.1 ± 20.1 30.4 ± 19.1 24.9 ± 19.4 24.8 ± 20.3 p=0.041 
NITBUT (s) 13.2 ± 2.4 13.3 ± 2.3 13.4 ± 2.5 13.6 ± 2.4 F=1.584, p=0.196 
NaFl TBUT (s) 13.3 ± 2.7 13.6 ± 2.4 13.9 ± 2.5 13.9 ± 2.5 p=0.259 
TMH (mm) 0.11 ± 0.01 0.11 ± 0.01 0.11 ± 0.01 0.11 ± 0.01 p=0.289 
Phenol Red Test 
(mm) 
14.3 ± 4.7 14.2 ± 4.2 14.2 ± 4.3 13.4 ± 4.2 p=0.221 
LIPCOF 1.5 ± 0.8 1.3 ± 0.8 1.3 ± 0.7 1.1 ± 0.8 p=0.038 
Corneal staining 0.06 ± 0.24 0.02 ± 0.14 0.04 ± 0.20 0.02 ± 0.14 p=0.629 
Conjunctival 
staining 
0.98 ± 0.94 0.80 ± 0.90 0.66 ± 0.80 0.52 ± 0.76 p=0.012 
Overall comfort 5.2 ± 2.9 5.5 ± 2.8 6.3 ± 2.6 6.5 ± 2.2 p=0.003 
Ease of insertion 6.8 ± 2.4 6.4 ± 2.4 6.6 ± 2.2 6.8 ± 2.1 p=0.339 
Visual clarity 6.3 ± 2.6 6.5 ± 2.3 6.9 ± 2.2 6.9 ± 1.9 p=0.036 
Table 4: Average ± SD of dry eye signs, symptoms and patient ratings after each 4 weeks of 
treatment with artificial tears. OSDI= Ocular Surface Disease Index; NITBUT= Non-
Invasive Tear Break-Up Time; NaFl TBUT = fluorescein Tear Break-Up Time, TMH= 
Tear Meniscus Height; LIPCOF= Lid Parallel Conjunctival Folds. Bold p values denote 
statistical significance. N=50.  
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Figure 4: Percentage of participants whose treatment preference matched the treatment that 
gave the largest improvement in signs and symptoms. OSDI= Ocular Surface Disease 
Index; NITBUT= Non-Invasive Tear Break-Up Time; NaFl TBUT = fluorescein Tear 
Break-Up Time, TMH= Tear Meniscus Height; LIPCOF= Lid Parallel Conjunctival Folds. 
n=50. 
 
Treatment preference 
After trialling all four treatments, 17 (34%) participants preferred Clinitas Soothe, 15 (30%) preferred 
TheraTears, 12 (24%) preferred Tears Again and 6 (12%) preferred Hyabak. Grouping the participants 
according to their treatment preference, the rating of overall comfort (Hyabak: 8.6 ± 1.0; Tears 
Again: 8.3 ± 1.0; TheraTears: 8.2 ± 1.5; Clinitas Soothe: 8.3 ± 1.2; p=0.117), ease of insertion (Hyabak: 
9.0 ± 1.3; Tears Again: 8.5 ± 1.1; TheraTears: 8.1 ± 1.7; Clinitas Soothe: 8.6 ± 1.1; p=0.233) and clarity 
of vision (Hyabak: 9.2 ± 1.2; Tears Again: 8.4 ± 1.1; TheraTears: 8.1 ± 1.7; Clinitas Soothe: 8.4 ± 1.5; 
p=0.091) by those that preferred each treatment after 4 weeks was not significantly different.  
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Can the drop preferred be predicted from baseline measures? 
Considering the baseline parameters, TheraTears was preferred by those with a lower tear volume 
and Tears Again was preferred by those with a thinner (lower grade) lipid film layer (Table 5).  
Clinitas Soothe and Hyabak preference could not be predicted from baseline measures (Table 5). 
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Clinitas Soothe 
Preferred 
Drop  
(n=17) 
58.4 ± 
17.1 
31.1 ± 
19.8 
13.5 ± 
2.0 
13.3 ± 
2.7 
0.11 ± 
0.02 
16.4 ± 
5.1 
1.8 ± 
0.6 
307.5 
± 10.6 
2.7 ± 
0.8 
Remaining 
Subjects  
(n=33) 
62.0 ± 
12.5 
35.3 ± 
20.3 
13.1 ± 
1.9 
13.1 ± 
2.3 
0.11 ± 
0.02 
13.0 ± 
4.7 
1.5 ± 
0.8 
312.5 
± 20.2 
2.5 ± 
1.2 
p value 0.28 0.12 0.54 0.55 0.95 0.09 0.06 0.34 0.86 
Hyabak 
Preferred 
Drop (n=6) 
64.8 ± 
11.0 
38.8 ± 
22.8 
14.2 ± 
1.8 
14.1 ± 
2.2 
0.12 ± 
0.02 
14.8 ± 
6.1 
1.8 ± 
0.8 
315.5 
± 23.1 
2.8 ± 
0.8 
Remaining 
Subjects 
(n=44) 
60.2 ± 
14.6 
33.2 ± 
19.8 
13.1 ± 
1.9 
13.0 ± 
2.4 
0.11 ± 
0.02 
14.0 ± 
5.0 
1.5 ± 
0.8 
310.1 
±  16.9 
2.5 ± 
1.1 
p value 0.18 0.59 0.19 0.39 0.65 0.90 0.57 0.87 0.46 
Tears Again 
Preferred 
Drop 
(n=12) 
60.6 ± 
14.0 
33.6 ± 
24.5 
13.4 ± 
1.5 
12.9 ± 
2.0 
0.11 ± 
0.02 
14.1 ± 
3.6 
1.0 ± 
0.9 
318.1 
± 25.8 
2.4 ± 
0.8 
Remaining 
Subjects 
(n=38) 
60.8 ± 
14.4 
33.9 ± 
18.8 
13.1 ± 
2.1 
13.3 ± 
2.5 
0.11 ± 
0.02 
14.2 ± 
5.5 
1.8 ± 
0.7 
308.5 
± 13.7 
2.7 ± 
1.1 
p value 0.94 0.46 0.62 0.65 0.57 0.77 0.05 0.51 0.04 
TheraTears 
Preferred 
Drop 
(n=15) 
64.1 ± 
9.5 
35.2 ± 
16.7 
12.3 ± 
2.0 
12.8 ± 
2.5 
0.11 ± 
0.03 
11.3 ± 
4.8 
1.7 ± 
0.7 
306.8 
± 12.5 
2.6 ± 
1.4 
Remaining 
Subjects 
(n=35) 
59.4 ± 
15.7 
33.3 ± 
21.5 
13.6 ± 
1.8 
13.3 ± 
2.4 
0.11 ± 
0.02 
15.3 ± 
4.8 
1.5 ± 
0.8 
312.5 
± 19.3 
2.5 ± 
0.9 
p value 0.62 0.85 0.31 0.85 0.39 0.01 0.27 0.30 0.99 
Table 5: Comparison of age and baseline signs and symptoms of the participants who 
preferred each treatment type, compared to the remaining cohort (average ± 
standard deviation). OSDI= Ocular Surface Disease Index; NITBUT= Non-Invasive Tear 
Break-Up Time; NaFl TBUT = fluorescein Tear Break-Up Time, TMH= Tear Meniscus 
Height; LIPCOF= Lid Parallel Conjunctival Folds. Bold p values denote statistical 
significance.  
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Did the preferred artificial tear give patients better signs or symptoms compared to the other drops 
trialled? 
Intrasubject differences in OSDI, NITBUT, TMH, LIPCOF and NaFl TBUT results were not dependent 
on treatment type amongst the participants who preferred Clinitas Soothe, TheraTears, Tears Again 
or Hyabak (Table 6). However, participants who preferred Clinitas Soothe or TheraTears reported 
subjective overall comfort, ease of insertion and clarity of vision was superior after treatment with 
their preferred treatment when compared to the other treatment options (Table 6). Despite no 
differences in reported overall comfort, participants who preferred Tears Again found this treatment 
provided better clarity of vision and was easier to insert than the other treatment options. Whereas, 
participants who preferred Hyabak reported significantly better overall comfort with no significant 
difference in ease of insertion or clarity of vision after using Hyabak drops when compared to the 
other treatment options. 
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Clinitas Soothe (n=17) 
Preferred 
Drop 
25.1 ± 
18.4 
13.7 
+2.1 
13.8 ± 
2.4 
0.11 ± 
0.01 
15.5 ± 
4.6 
1.4 ± 
0.9 
8.3 ± 
1.2 
8.6 ± 
1.0 
8.4 ± 
1.5 
Non-
Preferred 
drops 
25.2 ± 
18.5 
14.1 ± 
2.1 
14.2 ± 
2.3 
0.11  ± 
0.01 
15.6 ± 
4.4 
1.2 ± 
0.8 
6.1 ± 
2.8 
7.1 ± 
2.4 
7.2 ± 
2.0 
p value 0.756 0.408 0.932 0.053 0.924 0.689 0.048 0.014 0.041 
Hyabak (n=6) 
Preferred 
Drop  
24.8 
+26.8 
15.1 
+2.0 
14.9 
+1.5 
0.11 
+0.01 
14.8 
+3.5 
1.0 
+0.9 
8.6 
+1.0 
9.0 
+1.3 
9.2 
+1.2 
Non-
Preferred 
drops 
30.7 
+24.2 
13.9 
+1.7 
14.5 
+1.6 
0.11 
+0.01 
14.7 
+4.2 
1.3 
+0.6 
6.2 
+3.0 
7.5 
+2.1 
7.6 
+2.1 
p value 0.042 0.278 0.674 0.102 0.785 0.234 0.042 0.066 0.068 
Tears Again (n=12) 
Preferred 
Drop  
22.3 ± 
18.2 
13.3 
+2.3 
13.7 
+2.3 
0.11 
+0.01 
13.6 
+4.1 
1.3 
+0.6 
8.3 
+1.0 
8.5 
+1.1 
8.4 
+1.1 
Non-
Preferred 
drops 
27.7 ± 
21.0 
13.3 
+2.4 
13.8 
+2.8 
0.11 
+0.01 
13.3 
+4.3 
1.1 
+0.7 
5.8 
+2.7 
6.2 
+2.2 
5.9 
+2.6 
p value 0.937 0.788 0.969 0.516 0.637 0.271 0.081 0.036 0.036 
TheraTears (n=15) 
Preferred 
Drop 
35.6 ± 
19.1 
12.4 ± 
2.5 
12.7 ± 
2.6 
0.11 ± 
0.02 
12.8 ± 
4.5 
1.7 ± 
0.7 
8.2 ± 
1.5 
8.1 ± 
1.7 
8.1 ± 
1.7 
Non-
Preferred 
drops 
28.1 ± 
19.2 
12.5 ± 
2.7 
12.8 ± 
2.9 
0.11 ± 
0.02 
12.4 ± 
3.8 
1.5 ± 
0.8 
5.5 ± 
2.5 
6.4 ± 
2.1 
6.4 ± 
2.0 
p value 0.256 0.703 0.589 0.749 0.932 0.887 0.002 0.022 0.013 
Table 6: Comparison of signs, symptoms and subjective ratings after treatment with each 
individual’s preferred treatment and the results attained after the same participants 
used the other treatments available (average ± standard deviation). OSDI= Ocular 
Surface Disease Index; NITBUT= Non-Invasive Tear Break-Up Time; NaFl TBUT = 
fluorescein Tear Break-Up Time, TMH= Tear Meniscus Height; LIPCOF= Lid Parallel 
Conjunctival Folds. Bold p values denote statistical significance. 
 
The preferred treatment preference afforded the greatest improvement in OSDI, NITBUT, NaFl TBUT, 
TMH, PRT and LIPCOF in less than 50% of participants (Figure 4).  
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Discussion 
The current investigation is one of few randomised controlled crossover trial to examine the 
subjective and objective ocular surface impact of a range of commercially available dry eye 
treatments and the first to provide evidence-based criteria indicating which composition of 
treatment is best suited to alleviate particular dry eye signs and symptoms. Baseline measures 
confirm all the patients would be diagnosed with dry eye disease according to the new TFOS DEWS II 
criteria (symptoms and tear film instability, hyperosmolarity or ocular surface staining) [27]. Tear 
film stability was generally above the cut off required for diagnosis, whereas tear volume as 
indicated by the TMH was low, suggesting the general cohort of patients’ dry eye was more aqueous 
deficient than evaporative in nature.  
Whilst the impact of each dry eye treatment on OSDI, NITBUT, NaFl TBUT, TMH, PRT, LIPCOF, NaFl 
corneal staining and conjunctival staining results was similar, OSDI, LIPCOF and conjunctival staining 
measurements significantly improved from baseline following the completion of the study. The 
observed improvement in conjunctival tissue could feasibly be associated with an improvement in 
the mucus layer of the tear film, which would ameliorate the entire tear film; however a significant 
improvement in the quality and volume of the tear film was not observed during the course of the 
study. Nevertheless, it is possible a commensurate improvement in tear quality and volume may be 
observed after a longer duration of treatment or more sensitive tests such as Optical Coherence 
Tomography analysis of tear meniscus area. The improvement in the conjunctival tissue, but not 
corneal signs, in the duration of the study also suggests this could be a more sensitive tissue for 
assessing the efficacy of dry eye treatments.  
Considering the treatment preference of each participant, Clinitas Soothe and Theratears were the 
most popular treatment options, followed by Tears Again and Hyabak. It is likely Clinitas Soothe was 
preferred by more participants than Hyabak due to the higher concentration of sodium hyaluronate 
contained in Clinitas Soothe (0.4%) when compared to Hyabak (0.15%), as found previously [2]. 
19 
 
Beside the concentration of sodium hyaluronate the molecular weight forms of hyaluronan have 
distinct effects on CD44 clustering [28]. Sodium hyaluronate increases tear film stability by 
increasing tear film viscosity between blinks [2]. Clinical trials of sodium hyaluronate dry eye 
treatment have reported an increase in ocular comfort [1-4,15], a reduction in NaFl corneal staining 
[3], a reduction in Rose Bengal staining [28], an increase in NITBUT [2,4], an increase in Schirmer’s 
score [29] and an improvement in impression cytology grading [16]. Sodium hyaluronate is a 
naturally occurring glycosaminoglycan of the extracellular matrix and a ligand for the hyaluronate 
receptor CD44 [30]. Activation of CD44 promotes the interaction with cytoskeletal proteins, 
facilitating cellular migration [5,6,31,32]. CD44 is over-expressed within conjunctival and corneal 
cells of patients with dry eye [13] and corneal inflammation [29]. Sodium hyaluronate has a high 
affinity for CD44 receptors and tri-daily application of sodium hyaluronate for 2 months has been 
shown to significantly reduce the expression of CD44 [15]. Therefore, it is likely sodium hyaluronate 
dry eye drops help to protect the ocular surface [33], promote faster wound healing [5,6] and reduce 
ocular surface inflammation [34], thus relying on measurements of tear stability at baseline may not 
indicate which patients may benefit from sodium hyaluronate dry eye treatment as found in this 
study.  
Hyabak provided superior overall comfort when compared to the other treatments trialled by 
participants who preferred Hyabak. However, Hyabak gave the largest improvement in OSDI, 
NITBUT, TMH, PRT, LIPCOF and NaFl TBUT of all the treatments trialled in less than 35% of 
participants who preferred Hyabak, indicating a weak correlation between subjective dry eye 
symptoms and objective measurements, as reported previously [35]. Similar results were observed 
for participants who preferred Clinitas Soothe, however the proportion of participants attaining the 
largest improvement in TMH and PRT with Clinitas Soothe approached 50%. Future dry eye studies 
should consider measuring expression of CD44 to determine the utility of CD44 expression to select 
patients (when clinical tests become available) who are likely to respond positively to sodium 
hyaluronate treatment.   
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TheraTears was preferred by participants with a lower tear volume at baseline, as quantified by the 
Phenol Red Test, but this was not supported by TMH data, perhaps due to a lack of sensitivity in the 
latter test when assessed subjectively. The key lubricating ingredient in TheraTears is 
carboxymethylcellulose (CMC), which is a mucomimetic [36] that exhibits a high affinity for 
bioadhesion [7]. The mucus layer is essential for corneal wettability and adherence of the tear film 
[37]. In addition, CMC has been shown to stimulate corneal epithelial cell migration [8] and a 
significant improvement in goblet cell density has been observed after one month of CMC treatment 
[38], further enhancing the mucus layer of the tear film. A reduction in goblet cell density is likely to 
be associated with ocular surface inflammation and loss of vascularisation [39] and appears to be an 
early sign of an abnormality of epithelial differentiation (also examined using impression cytology) 
[40,41].  
Brignole et al. [15] utilised flow cytology in impression cytology specimens to show the reduction in 
expression of CD44 was superior following treatment with sodium hyaluronate when compared to 
CMC eye drops, however CMC does not bind to CD44, and instead, is thought to bind to glucose 
receptor GluT-1 to stimulate cellular migration [8]. A significant improvement in comfort [3,41],  
TBUT [3], NaFl corneal staining [3] and Schirmer’s test [40] has been reported following CMC dry eye 
treatment, which was similar to the improvement attained following sodium hyaluronate treatment, 
as found by the current study. Additionally, TheraTears also has a patented hypotonic electrolyte 
balance that reduces elevated tear osmolarity,[42] reversing the osmotic gradient and ensuring the 
tear film hydrates the ocular surface and prevents ocular tissue dessication. Hypotonic 0.4% sodium 
hyaluronate eye drops produced a greater improvement in Rose Bengal staining, fluorescein 
staining, TBUT and impression cytology grade than isotonic 0.4% sodium hyaluronate eye drops 
amongst individuals with Sjögren’s syndomen [34]. However, participants who preferred TheraTears 
did not have significantly different tear osmolarity at baseline than the remaining cohort, therefore 
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it is likely the aforementioned benefits of CMC may have been primarily responsible for the 
subjective improvement in dry eye symptoms. 
Similarly to Clinitas Soothe, TheraTears provided superior overall comfort, ease of instillation and 
clarity of vision to those patients that preferred it when compared to the other treatments trialled 
by those participants; however TheraTears gave the largest improvement in OSDI, NITBUT, TMH, 
PRT, LIPCOF and NaFl TBUT of all the treatments trialled in less than 30% of participants who 
preferred TheraTears. Perhaps futures dry eye studies should consider assessing the mucus phase of 
the tear film and the expression of CMC receptors in order to aid identification (when clinical tests 
become available) of patients who are likely to respond positively to treatment containing CMC.   
As expected, Tears Again was preferred by participants with a thinner lipid tear film layer at baseline. 
Tears Again is a phospholipid (phosphatidylcholine) liposomal spray, which is applied to closed 
eyelids, allowing liposomes to leach into the tear film via the lid margins, integrating with the 
habitual lipid reservoir and spreading across the tear film during each blink [9-11]. The stability and 
evaporation rate of the tear film depends on the lipid layer [43,44]. The lipid layer of the tear film 
reduces aqueous evaporation by 90 to 95% and reduces the surface-tension of the tear film phase by 
approximately 25% [43]. Therefore, rebuilding and enhancing the lipid tear film layer aims to reduce 
aqueous evaporation [12] and increase tear film stability [9], although this was not evident in the 
timescale of this study. A significant improvement in comfort [9-11], lipid layer thickness [9], NITBUT 
[9-11], LIPCOF [10,12] and Schirmer’s results [12] have been reported following treatment with 
liposomal sprays. However, Tears Again gave the largest improvement in OSDI, NITBUT, TMH, PRT, 
LIPCOF and NaFl TBUT of all the treatments trialled in less than 35% of participants who preferred 
Tears Again in the current study, indicating a weak correlation between subjective and objective 
measurements. It is feasible the relative ease of instillation of the spray compared to traditional eye 
droppers may have factored highly in a participant’s judgement of overall treatment preference. 
Indeed, Lee et al. [12] stated 100% of 382 patients found application with a spray was favourable to 
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eye droppers. Participants from the current study who preferred Tears Again reported the ease of 
instillation and clarity of vision was significantly superior compared to the other treatment options, 
whereas the overall comfort of Tears Again was not statistically significantly better than the other 
treatments trialled by the participants preferring Tears Again.  
In conclusion, one type of dry eye treatment was not capable of adequately treating the dry eye 
symptoms of all participants. Assessment of the tear film using a battery of tests is required in order 
to determine the type of dry eye and to aid selection of the optimum dry eye treatment. Initial 
treatment effects were first seen in conjunctival tests so these may be a more sensitive tissue to 
assess dry eye treatment efficacy. Treatment effects were evident still after 4 months following 
initial treatment and this should be communicated to patients so they don’t reject prescribed 
treatments after short trials. It also suggests that artificial tears do provide more than transient relief 
to symptoms and aid in breaking the vicious dry eye disease cycle. The treatment that afforded the 
greatest improvement in clinical signs did not consistently match each individual’s preferred 
treatment. However, in terms of subjective preference, an artificial tear focused on balancing ocular 
surface osmolarity (TheraTears) was the most appropriate treatment for individuals with a low tear 
volume at baseline and a liposomal spray (Tears Again) was the most appropriate treatment for 
individuals with a lipid layer deficiency at baseline. Owing to the promotion of epithelial cell 
migration, eye drops containing sodium hyaluronate and CMC are also suitable for the treatment of 
ocular surface disorders and post-operative healing following corneal surgery, but newer clinical 
tests such as meibography and inflammatory marker indicators are required to determine patients 
for whom this should be the first choice treatment [37].     
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